CAD
Conditions
Brief summary
The purpose of the COAST clinical study data will be to utilize and to gain approval for commercializing the Micro Crown as part of the Coronary Orbital Atherectomy System (OAS).
Detailed description
This is a prospective, single-arm, multi-center, global study designed to evaluate performance of the Diamondback 360® Coronary Orbital Atherectomy System Micro Crown (OAS Micro Crown) in treating de novo, severely calcified coronary lesions.
Interventions
DEVICEDiamondback 360® Coronary OAS Micro Crown
The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
Sponsors
Abbott Medical Devices
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must be 18 or older. * Subjects must have a clinical indication for coronary intervention. * CK and CK-MB must be less than or equal to the upper limit of lab normal value within 8 hours prior to the procedure. * The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure. * The target vessel must be a native coronary artery. * The target vessel reference diameter must be \>= 2.5mm and \<= 4.0 mm. * The lesion length must not exceed 40 mm. * The target vessel must have a TIMI flow three (3) at baseline. * The target lesion must have fluoroscopic, IVUS or OCT evidence of severe calcium deposit at the lesion site. * The lesion must be crossable with the study guide wire.
Exclusion criteria
* Inability to understand the study requirements or has a history of non-compliance with medical advice. * Unwilling to sign the COAST ICF. * History of any cognitive or mental health status that would interfere with study participation. * Currently enrolled in any other pre-approval investigational study. * Female subjects who are pregnant or planning to become pregnant within the study period. * Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications. * Known sensitivity to contrast media, which cannot be adequately pre-medicated. * Diagnosed with chronic renal failure unless under hemodialysis, or has a serum creatinine level \> 2.5 mg/dl. * Experienced acute MI, STEMI or non-STEMI: CK-MB greater than the upper limit of lab normal value, within 30 days prior to index procedure. * History of major cardiac intervention within 30 days. * Evidence of heart failure * History of a stroke or TIA within six (6) months. * Active peptic ulcer or upper GI bleeding within six (6) months. * History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion, if one should become necessary. * Concurrent medical condition with a life expectancy of \< 12 months. * History of immune deficiency. * Uncontrolled insulin dependent diabetes. * Evidence of active infections on the day of the index procedure. * Subject has planned cardiovascular intervention within 60 days post index procedure. * Subject is not an acceptable candidate for emergent CABG surgery. * Subject with known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide. * Subject with angiographically confirmed evidence of more than one (1) lesion requiring intervention, unless the treatment of the lesions is staged. * Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass. * Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate or on-line QCA. * Target vessel has angiographically visible or suspected thrombus. * Target vessel has a stent from previous PCI. * Target vessel appears to be or is excessively tortuous at baseline. * Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left main lesion. * Target lesion is a bifurcation. * Target lesion has a ≥ 1.5 mm side branch. * Angiographic evidence of a dissection prior to initiation of OAD.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiac Event (MACE) | 30 Days | A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 30 days. 30-Day MACE is composed of: * Cardiac death * Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave * Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Procedural Success | Participants were followed from baseline procedure through the duration of hospital stay, an average of 50.4 hours | Procedural success was defined as success in facilitating stent delivery with a residual stenosis of \<50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions. |
Countries
Japan, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Diamondback 360® Coronary OAS Micro Crown Diamondback 360® Coronary OAS Micro Crown: The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall. | 100 |
| Total | 100 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 2 |
Baseline characteristics
| Characteristic | Diamondback 360® Coronary OAS Micro Crown |
|---|---|
| Age, Continuous | 70.7 years |
| Race/Ethnicity, Customized Asian | 2 participants |
| Race/Ethnicity, Customized Black or African American | 2 participants |
| Race/Ethnicity, Customized Japanese | 26 participants |
| Race/Ethnicity, Customized Other | 2 participants |
| Race/Ethnicity, Customized Unspecified | 3 participants |
| Race/Ethnicity, Customized White | 65 participants |
| Sex: Female, Male Female | 29 Participants |
| Sex: Female, Male Male | 71 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 9 / 100 |
| serious Total, serious adverse events | 27 / 100 |
Outcome results
Primary
Major Adverse Cardiac Event (MACE)
A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 30 days. 30-Day MACE is composed of: * Cardiac death * Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave * Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure
Time frame: 30 Days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Diamondback 360® Coronary OAS Micro Crown | Major Adverse Cardiac Event (MACE) | 85.0 Percent Probability of Freedom from MACE |
Secondary
Procedural Success
Procedural success was defined as success in facilitating stent delivery with a residual stenosis of \<50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions.
Time frame: Participants were followed from baseline procedure through the duration of hospital stay, an average of 50.4 hours
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Diamondback 360® Coronary OAS Micro Crown | Procedural Success | 85.0 percentage of procedures |